{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:02:12Z","timestamp":1784847732526,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastric cancer (GC) often exhibits resistance to anti-programmed death-1 (PD-1) immunotherapy. Immunogenic cell death (ICD) enhances antitumor immunity, and trifluridine\/tipiracil (FTD\/TPI) induces ICD and modulates immunity. Radiation therapy (RT) may trigger abscopal effects. We investigated whether FTD\/TPI combined with RT enhances tumor immunity in GC and its impact with PD-1 blockade. ICD induction by FTD and RT in YTN16 mouse GC cells was assessed by calreticulin, high-mobility group box 1 (HMGB1), and ATP evaluation. A dual subcutaneous YTN16 tumor model was established in C57BL\/6J mice; mice were treated with FTD\/TPI and RT (with irradiation of the first tumor). ICD was induced in vitro by FTD or RT and enhanced by the combination, as indicated by increased calreticulin surface expression and HMGB1 and ATP release. ICD induction in the first tumor was confirmed by HMGB1 release. FTD\/TPI\u2009+\u2009RT suppressed growth of the second tumor and enhanced antitumor immunity by increasing CD8\u207a T-cell infiltration and depleting M2 macrophages. PD-1 expression on CD8\u207a T cells increased after FTD\/TPI\u2009+\u2009RT; adding anti-PD-1 further suppressed the second tumor growth. Our findings support clinical trials of this triple-combination strategy in advanced GC, particularly in subgroups refractory to immune checkpoint blockade.<\/jats:p>","DOI":"10.1038\/s41598-026-53689-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:58:05Z","timestamp":1779346685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trifluridine\/tipiracil enhances radiation-induced abscopal effects and augments PD-1 blockade in gastric cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Tetsuya","family":"Asakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Doden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Inaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"53689_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"53689_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet 396, 635\u2013648. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5 (2020).","journal-title":"Lancet"},{"key":"53689_CR3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5 (2017).","journal-title":"Lancet"},{"key":"53689_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J. Clin. Oncol. 42, 2012\u20132020. https:\/\/doi.org\/10.1200\/JCO.23.01601 (2024).","journal-title":"J. Clin. Oncol."},{"key":"53689_CR5","doi-asserted-by":"publisher","unstructured":"Luo, C. et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell. Death Discov. 11 https:\/\/doi.org\/10.1038\/s41420-024-02364-x (2025).","DOI":"10.1038\/s41420-024-02364-x"},{"key":"53689_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01580-9","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. First-line immunotherapy for advanced HER2-negative gastric cancer: updates on clinical evidence and potential factors associated with the efficacy and predictors of immunotherapy response. Gastric Cancer. https:\/\/doi.org\/10.1007\/s10120-024-01580-9 (2024).","journal-title":"Gastric Cancer"},{"key":"53689_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361. https:\/\/doi.org\/10.1038\/nm1523 (2007).","journal-title":"Nat. Med."},{"key":"53689_CR8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059. https:\/\/doi.org\/10.1038\/nm1622 (2007).","journal-title":"Nat. Med."},{"key":"53689_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","volume":"38","author":"Y Ma","year":"2013","unstructured":"Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729\u2013741. https:\/\/doi.org\/10.1016\/j.immuni.2013.03.003 (2013).","journal-title":"Immunity"},{"key":"53689_CR10","doi-asserted-by":"publisher","first-page":"13263","DOI":"10.1111\/imr.13263","volume":"326","author":"F Ghiringhelli","year":"2024","unstructured":"Ghiringhelli, F. et al. Using immunogenic cell death to improve anticancer immunotherapies. Immunol. Rev. 326, 13263. https:\/\/doi.org\/10.1111\/imr.13263 (2024).","journal-title":"Immunol. Rev."},{"key":"53689_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum, R. R. et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365\u2013379. https:\/\/doi.org\/10.1038\/nrclinonc.2016.211 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53689_CR12","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618. https:\/\/doi.org\/10.1038\/ncomms15618 (2017).","journal-title":"Nat. Commun."},{"key":"53689_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.adro.2018.08.021","volume":"3","author":"EC Ko","year":"2018","unstructured":"Ko, E. C., Benjamin, K. T. & Formenti, S. C. Generating antitumor immunity by targeted radiation therapy: role of dose and fractionation. Adv. Radiat. Oncol. 3, 486\u2013493. https:\/\/doi.org\/10.1016\/j.adro.2018.08.021 (2018).","journal-title":"Adv. Radiat. Oncol."},{"key":"53689_CR14","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody. Clin. Cancer Res. 15, 5379\u20135388 (2009). 10.1158\/1078\u2009\u2013\u20090432.CCR-09-0265.","journal-title":"Clin. Cancer Res."},{"key":"53689_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","volume":"16","author":"C Grassberger","year":"2019","unstructured":"Grassberger, C., Ellsworth, S. G., Wilks, M. Q., Keane, F. K. & Loeffler, J. S. Assessing the interactions between radiotherapy and antitumour immunity. Nat. Rev. Clin. Oncol. 16, 729\u2013745. https:\/\/doi.org\/10.1038\/s41571-019-0238-9 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53689_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/bjr\/tqae100","volume":"97","author":"K Passelli","year":"2024","unstructured":"Passelli, K., Rep\u00e1raz, D., Kinj, R. & Herrera, F. G. Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy. Br. J. Radiol. 97, 1378\u20131390. https:\/\/doi.org\/10.1093\/bjr\/tqae100 (2024).","journal-title":"Br. J. Radiol."},{"key":"53689_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal. Transduct. Target. Ther. 8, 205. https:\/\/doi.org\/10.1038\/s41392-023-01462-z (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"53689_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J. Clin. Oncol. 36, 350\u2013358. https:\/\/doi.org\/10.1200\/JCO.2017.74.3245 (2018).","journal-title":"J. Clin. Oncol."},{"key":"53689_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448. https:\/\/doi.org\/10.1016\/S1470-2045(18)30739-3 (2018).","journal-title":"Lancet Oncol."},{"key":"53689_CR20","doi-asserted-by":"publisher","first-page":"16969","DOI":"10.1038\/s41598-017-17282-5","volume":"7","author":"R Nakanishi","year":"2017","unstructured":"Nakanishi, R. et al. Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine\/tipiracil medication. Sci. Rep. 7, 16969. https:\/\/doi.org\/10.1038\/s41598-017-17282-5 (2017).","journal-title":"Sci. Rep."},{"key":"53689_CR21","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.21873\/anticanres.13502","volume":"39","author":"T Kobunai","year":"2019","unstructured":"Kobunai, T., Matsuoka, K. & Takechi, T. ChIP-seq analysis to explore DNA replication profile in trifluridine-treated human colorectal cancer cells in vitro. Anticancer Res. 39, 3565\u20133570. https:\/\/doi.org\/10.21873\/anticanres.13502 (2019).","journal-title":"Anticancer Res."},{"key":"53689_CR22","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto, K. et al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2032-deoxy-5-fluorouridine into DNA. Int. J. Oncol. 46, 2327\u20132334. https:\/\/doi.org\/10.3892\/ijo.2015.2974 (2015).","journal-title":"Int. J. Oncol."},{"key":"53689_CR23","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/2326-6066.CIR-19-0228","volume":"7","author":"E Limagne","year":"2019","unstructured":"Limagne, E. et al. Trifluridine\/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages. Cancer Immunol. Res. 7, 1958\u20131969. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0228 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"53689_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","volume":"5","author":"SR Gameiro","year":"2014","unstructured":"Gameiro, S. R. et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5, 403\u2013416. https:\/\/doi.org\/10.18632\/oncotarget.1719 (2014).","journal-title":"Oncotarget"},{"key":"53689_CR25","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","volume":"25","author":"L Bezu","year":"2018","unstructured":"Bezu, L. et al. eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death. Cell. Death Differ. 25, 1375\u20131393. https:\/\/doi.org\/10.1038\/s41418-017-0044-9 (2018).","journal-title":"Cell. Death Differ"},{"key":"53689_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2020.08.038","volume":"493","author":"K Rothkamm","year":"2020","unstructured":"Rothkamm, K. et al. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine\/tipiracil and X-rays. Cancer Lett. 493, 179\u2013188. https:\/\/doi.org\/10.1016\/j.canlet.2020.08.038 (2020).","journal-title":"Cancer Lett."},{"key":"53689_CR27","doi-asserted-by":"publisher","unstructured":"Selvin, T. et al. Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model. Sci. Rep. 12 https:\/\/doi.org\/10.1038\/s41598-022-16077-7 (2022).","DOI":"10.1038\/s41598-022-16077-7"},{"key":"53689_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019 (2014).","journal-title":"Immunity"},{"key":"53689_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2 (2021).","journal-title":"Lancet"},{"key":"53689_CR30","doi-asserted-by":"publisher","first-page":"103967","DOI":"10.1016\/j.esmoop.2024.103967","volume":"9","author":"V Formica","year":"2024","unstructured":"Formica, V. et al. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. ESMO Open. 9, 103967. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103967 (2024).","journal-title":"ESMO Open."},{"key":"53689_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8\u2009+\u2009T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223. https:\/\/doi.org\/10.1038\/s41577-021-00574-3 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"53689_CR32","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13569","volume":"109","author":"M Yamamoto","year":"2018","unstructured":"Yamamoto, M. et al. Established gastric cancer cell lines transplantable into C57BL\/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 109, 1480\u20131492. https:\/\/doi.org\/10.1111\/cas.13569 (2018).","journal-title":"Cancer Sci."},{"key":"53689_CR33","doi-asserted-by":"publisher","first-page":"27499","DOI":"10.1038\/s41598-025-11887-x","volume":"15","author":"Y Fujiwara","year":"2025","unstructured":"Fujiwara, Y. et al. Regulatory B cells drive immune evasion in the tumor microenvironment and are involved in peritoneal metastasis of gastric cancer. Sci. Rep. 15, 27499. https:\/\/doi.org\/10.1038\/s41598-025-11887-x (2025).","journal-title":"Sci. Rep."},{"key":"53689_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10120-021-01275-5","volume":"25","author":"Y Nakamura","year":"2022","unstructured":"Nakamura, Y. et al. Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast. Gastric Cancer. 25, 515\u2013526. https:\/\/doi.org\/10.1007\/s10120-021-01275-5 (2022).","journal-title":"Gastric Cancer"},{"key":"53689_CR35","doi-asserted-by":"publisher","first-page":"e003663","DOI":"10.1136\/jitc-2021-003663","volume":"10","author":"X Bai","year":"2022","unstructured":"Bai, X. et al. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J. Immunother Cancer. 10, e003663. https:\/\/doi.org\/10.1136\/jitc-2021-003663 (2022).","journal-title":"J. Immunother Cancer"},{"key":"53689_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1292\/jvms.24-0361","volume":"87","author":"M Yokosuka","year":"2025","unstructured":"Yokosuka, M., Osaka, M. & Tohei, A. Combined medetomidine, midazolam, and butorphanol anesthesia in mice has a central stress-relieving effect similar to that of isoflurane anesthesia. J. Vet. Med. Sci. 87, 402\u2013406. https:\/\/doi.org\/10.1292\/jvms.24-0361 (2025).","journal-title":"J. Vet. Med. Sci."},{"key":"53689_CR37","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-19-1344","volume":"25","author":"R Luo","year":"2019","unstructured":"Luo, R. et al. Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3\/CXCL10-mediated T-cell recruitment. Clin. Cancer Res. 25, 7243\u20137255 (2019). https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1344.","journal-title":"Clin. Cancer Res."},{"key":"53689_CR38","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H. & Fukushima, M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int. J. Oncol. 25, 571\u2013578.\u00a0https:\/\/doi.org\/10.3892\/ijo.25.3.571 (2004).","journal-title":"Int. J. Oncol."},{"key":"53689_CR39","unstructured":"American Veterinary Medical Association. AVMA guidelines for the euthanasia of animals: 2020 edition (American Veterinary Medical Association, 2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53689-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53689-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:46:12Z","timestamp":1784846772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53689-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53689"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53689-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23124"}}